Hematological aspects of Crimean-Congo hemorrhagic fever


Duru F., Fisgin T.

TURKISH JOURNAL OF HEMATOLOGY, vol.26, no.4, pp.161-166, 2009 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Review
  • Volume: 26 Issue: 4
  • Publication Date: 2009
  • Journal Name: TURKISH JOURNAL OF HEMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.161-166
  • Keywords: Crimean-Congo hemorrhagic fever, hematological manifestation, hemophagocytosis, FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, ORAL RIBAVIRIN, CYCLOSPORINE-A, CLINICAL-FEATURES, RISK-FACTORS, TURKEY, EFFICACY, THERAPY, VIRUS, INTERLEUKIN-18
  • Ondokuz Mayıs University Affiliated: Yes

Abstract

Crimean-Congo hemorrhagic fever (CCHF) is an acute tick-borne viral disease transmitted to humans by Hyalomma ticks or by direct contact with the blood of infected humans or domestic animals. In certain areas of the world, including Africa, Asia, South East Europe and Middle East, sporadic cases or outbreaks of CCHF have been reported. During the last six-year period from 2003 to 2009, CCHF has also occurred endemically in Turkey, particularly during spring and summer, with a case-fatality rate of approximately 5%, The disease is characterized by acute fever, nausea, vomiting, headache, myalgia, elevated liver enzymes and hemorrhagic manifestations ranging from mucocutaneous bleeding to life-threatening massive hemorrhage with disseminated intravascular coagulation (DIC) and hemophagocytosis. As with other viral hemorrhagic diseases, activation of lymphocytes, monocytes, macrophages and oversecretion of cytokines play a pivotal role in the pathogenesis and prognosis of CCHF. Recently an increasing number of publications on CCHF have been emerging in the literature, majority of which have been written by infection specialists. In this article, recent literature on CCHF has been reviewed, with particular emphasis on hematological manifestations, pathogenesis and therapeutic approaches in CCHF from the hematologist's point of view. (Turk J Hematol 2009; 26: 161-6)